Skip to main content

Enzalutamide Approved for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence: Stephen Freedland, MD

The FDA recently granted approval to enzalutamide (enza) for the treatment of nonmetastatic castration-sensitive prostate cancer (nmCRPC) with biochemical recurrence, based on the results of the phase 3 EMBARK trial. Following the approval, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, co-lead investigator of the trial, sat down to share more about its significance for patients with high-risk prostate cancer and biochemical recurrence.  

Continue reading

Enzalutamide Approved for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence: Stephen Freedland, MD

The FDA recently granted approval to enzalutamide (enza) for the treatment of nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence, based on the results of the phase 3 EMBARK trial. Following the approval, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, co-lead investigator of the trial, sat down to share more about its significance for patients with high-risk prostate cancer and biochemical recurrence.

Continue reading

Enzalutamide Approved for Non-Metastatic Castration-Sensitive Prostate Cancer with Biochemical Recurrence

The FDA has approved enzalutamide (Xtandi®, Astellas Pharma US, Inc.) for nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).   Why it matters: "Within 10 years following definitive therapy for prostate cancer, 20% to 50% of patients have BCR characterized by a rise in prostate-specific antigen (PSA) levels," wrote Dr. Stephen Freedland, Director of the Center for Integrated Research in Cancer and Lifestyle at ...

Continue reading

Talazoparib Plus Enzalutamide Approved for HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer

The FDA has approved talazoparib (Talzenna®, Pfizer, Inc.) in addition to enzalutamide for homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer (mCRPC).   Why it matters: "Despite significant advances in the therapeutic landscape of mCRPC in recent years, currently available therapies are not curative, and subsequent progression of disease usually reflects reactivation of the androgen receptor (AR) signaling pathway. Therefore, new therapeutic a...

Continue reading

Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer: Andrew J. Armstrong, MD, MSc

​The FDA recently added a new approval of enzalutamide (Xtandi®, Astellas Pharma Inc.) for the treatment of metastatic castration-sensitive prostate cancer, based on data from the ARCHES and ENZAMET trials. In this interview with i3 Health, Andrew J. Armstrong, MD, MSc, lead researcher of the phase 3 ARCHES trial, discusses the approval's significance and compares the variety of options that are now available for the treatment of metastatic hormone-sensitive disease. What are the greatest challe...

Continue reading